Moleculin Biotech, INC. (MBRX) — SEC Filings

Overview

Moleculin Biotech, INC. (MBRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 15, 2026: Moleculin Biotech, Inc. filed an EFFECT form on April 15, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999999995-26-001181, relates to Act 33 and has file number 333-294686. The company's business address is 5300 Memorial Drive, Suite 950, Housto

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 4 bearish, 42 neutral, 4 mixed. The dominant filing sentiment for Moleculin Biotech, INC. is neutral.

Filing Type Overview

Moleculin Biotech, INC. (MBRX) has filed 1 EFFECT, 39 8-K, 3 10-Q, 2 DEF 14A, 3 S-1/A, 1 S-1, 1 10-K/A with the SEC between Apr 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (50)

• Moleculin Biotech Filing Effectiveness Notice — EFFECT · Apr 15, 2026 Risk: low
  Moleculin Biotech, Inc. filed an EFFECT form on April 15, 2026, indicating the effectiveness of a registration statement. The filing, with accession number 9999
• Moleculin Biotech Enters Material Definitive Agreement — 8-K · Dec 22, 2025 Risk: medium
  On December 21, 2025, Moleculin Biotech, Inc. entered into a material definitive agreement. The company, headquartered in Houston, TX, filed an 8-K report detai
• Moleculin Biotech Files 8-K — 8-K · Dec 17, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on December 17, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD Discl
• Moleculin Biotech Files 8-K — 8-K · Dec 16, 2025 Risk: low
  On December 15, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 5300 Memorial D
• Moleculin Biotech Files 8-K: Material Agreement & Equity Sales — 8-K · Dec 10, 2025 Risk: medium
  On December 9, 2025, Moleculin Biotech, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
• 8-K Filing — 8-K · Dec 9, 2025
• 8-K Filing — 8-K · Dec 8, 2025
• 8-K Filing — 8-K · Nov 28, 2025
• Moleculin Biotech Files 8-K — 8-K · Nov 24, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on November 24, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD Discl
• 8-K Filing — 8-K · Nov 21, 2025
• Moleculin Biotech's Net Loss Widens to $49.1M Amid Warrant Issuances — 10-Q · Nov 13, 2025 Risk: high
  Moleculin Biotech, Inc. (MBRX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $49.112 million, a substantial
• 8-K Filing — 8-K · Nov 12, 2025
• Moleculin Biotech Files 8-K with Corporate Updates — 8-K · Oct 30, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on October 30, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the com
• Moleculin Biotech Files 8-K Report — 8-K · Oct 29, 2025 Risk: low
  On October 29, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
• Moleculin Biotech Files 8-K — 8-K · Oct 23, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on October 23, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD Disclo
• Moleculin Biotech Files 8-K on Security Holder Vote — 8-K · Oct 16, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on October 16, 2025, reporting on the submission of matters to a vote of security holders. The filing details the company's
• Moleculin Biotech Files 8-K Report — 8-K · Sep 25, 2025 Risk: low
  On September 25, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits
• Moleculin Seeks Shareholder Nod for 64.8M Warrant Issuance, Name Change — DEF 14A · Sep 15, 2025 Risk: high
  Moleculin Biotech, Inc. (MBRX) is holding a Special Meeting on October 16, 2025, to address three key proposals. The primary proposal, the Nasdaq Proposal, seek
• Moleculin Biotech Files 8-K with Exhibits — 8-K · Sep 9, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on September 9, 2025, reporting on events that occurred on the same date. The filing includes financial statements and exhi
• Moleculin Biotech Files 8-K with Corporate Updates — 8-K · Sep 8, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on September 8, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the
• Moleculin Biotech Files 8-K: Material Agreement & Equity Sales — 8-K · Aug 29, 2025 Risk: medium
  Moleculin Biotech, Inc. announced on August 28, 2025, that it entered into a material definitive agreement. The company also disclosed unregistered sales of equ
• Moleculin Biotech Files 8-K with Corporate Updates — 8-K · Aug 27, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on August 27, 2025, reporting an event on August 21, 2025. The filing indicates amendments to its Articles of Incorporation
• Moleculin Biotech Files 8-K on Shareholder Votes — 8-K · Aug 18, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on August 18, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corp
• Moleculin Biotech Files 8-K on Financials — 8-K · Aug 13, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on August 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statement
• Moleculin Biotech Burns Cash, Raises Capital Amidst Zero Revenue — 10-Q · Aug 12, 2025 Risk: high
  Moleculin Biotech, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company's net loss for
• Moleculin Biotech Files 8-K with Financials and Disclosures — 8-K · Aug 6, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on August 6, 2025, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the co
• Moleculin Biotech Files 8-K Current Report — 8-K · Aug 1, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on August 1, 2025, reporting an event that occurred on the same date. The filing is a current report pursuant to Section 13
• Moleculin Biotech Files 8-K — 8-K · Jul 30, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on July 30, 2025, reporting on financial statements and exhibits. The filing does not appear to contain new material events
• Moleculin Biotech Files 8-K with Corporate Updates — 8-K · Jul 17, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on July 17, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the com
• Moleculin Biotech Files 8-K: Material Agreement & Exhibits — 8-K · Jul 11, 2025 Risk: medium
  On July 11, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also includes f
• Moleculin Biotech Files 8-K Report — 8-K · Jul 9, 2025 Risk: low
  On July 9, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing indicates that the company is providing information related to Regulation FD Disclosure
• Moleculin Biotech Details Executive Equity Awards 2021-2024 — DEF 14A · Jul 8, 2025 Risk: medium
  Moleculin Biotech, Inc.'s DEF 14A filing, dated July 8, 2025, primarily details executive compensation and equity award information for the fiscal years 2021 th
• Moleculin Biotech Faces Delisting Concerns — 8-K · Jun 27, 2025 Risk: high
  Moleculin Biotech, Inc. filed an 8-K on June 27, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company is incorporat
• Moleculin Biotech Files 8-K: Material Agreement & Financials — 8-K · Jun 23, 2025 Risk: medium
  On June 20, 2025, Moleculin Biotech, Inc. entered into a material definitive agreement. The company also disclosed information related to Regulation FD and file
• Moleculin Biotech Files 8-K: Financials & Other Events — 8-K · Jun 18, 2025 Risk: low
  On June 18, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, and other events, indicating pot
• Moleculin Biotech Files S-1/A for Continuous Offering — S-1/A · Jun 16, 2025 Risk: high
  Moleculin Biotech, Inc. (MBRX) filed an S-1/A on June 16, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a strategic move t
• Moleculin Biotech Files S-1/A for Continuous Offering — S-1/A · Jun 11, 2025 Risk: high
  Moleculin Biotech, Inc. (MBRX) filed an S-1/A on June 11, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a potential capita
• Moleculin Biotech Amends S-1, Signals Future Capital Raise — S-1/A · Jun 6, 2025 Risk: high
  Moleculin Biotech, Inc. (MBRX) filed an S-1/A on June 6, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a strategic move to
• Moleculin Biotech Files 8-K with Financials — 8-K · Jun 5, 2025 Risk: low
  On June 5, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures
• Moleculin Biotech Files 8-K — 8-K · Jun 4, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on June 4, 2025, reporting on events that occurred on the same date. The filing includes financial statements and exhibits,
• Moleculin Biotech Files S-1 for Continuous Offering — S-1 · Jun 2, 2025 Risk: high
  Moleculin Biotech, Inc. (MBRX) filed an S-1 registration statement on June 2, 2025, for a delayed or continuous offering of securities under Rule 415, indicatin
• Moleculin Biotech Faces Delisting Concerns — 8-K · May 23, 2025 Risk: high
  Moleculin Biotech, Inc. filed an 8-K on May 23, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company, i
• Moleculin Biotech Files 8-K on Operations and Financials — 8-K · May 14, 2025 Risk: low
  On May 14, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well
• Moleculin Biotech Q1 2025: Cash Burn Continues — 10-Q · May 13, 2025 Risk: high
  Moleculin Biotech, Inc. filed its Q1 2025 10-Q report on May 13, 2025, for the period ending March 31, 2025. The company reported minimal revenue and significan
• Moleculin Biotech Files 8-K — 8-K · May 12, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on May 12, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
• Moleculin Biotech Files 8-K on Shareholder Votes — 8-K · May 9, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on May 9, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's corporat
• Moleculin Biotech Files 8-K — 8-K · May 7, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on May 7, 2025, reporting on events that occurred on the same date. The filing primarily concerns Regulation FD Disclosure
• Moleculin Biotech Files 8-K — 8-K · May 6, 2025 Risk: low
  On May 6, 2025, Moleculin Biotech, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No sp
• Moleculin Biotech Files 8-K with Corporate Updates — 8-K · May 5, 2025 Risk: low
  Moleculin Biotech, Inc. filed an 8-K on May 5, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company'
• Moleculin Biotech Files 2024 10-K Amendment — 10-K/A · Apr 30, 2025 Risk: medium
  Moleculin Biotech, Inc. filed an amendment (Amendment No. 2) to its annual report on Form 10-K for the fiscal year ended December 31, 2024. The filing was made

Related Companies

MOLN · NASDAQ

Frequently Asked Questions